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ABSTRACT
In normal subjects the main form of circulating insulin-like growth
factor (IGF) is the 150-kDa complex. This complex is formed by the
IGF peptide, the acid-stable IGF-binding protein-3 (IGFBP-3), and
the acid-labile subunit (ALS). Experimental and clinical data have
demonstrated that ALS is primarily under the control of GH and plays
a critical role in maintaining constant levels of circulating IGF-I. In
this study we evaluated ALS, IGF-I, and IGFBP-1, -2, and -3 in 45
acromegalic patients in basal conditions and, in 37 of these, twice after
surgical therapy compared with 100 age- and sex-matched control
subjects to estimate their value as parameter of GH secretory state.
The results demonstrated that in acromegaly before treatment all
parameters (ALS, 523 6 26; IGF-I, 129 6 6; IGFBP-1, 0.7 6 0.1;
IGFBP-3, 234 6 21; nmol/L; mean 6 SEM) but IGFBP-2 were signif-
icantly different (P , 0.0001) from those in healthy subjects (ALS,
281 6 4; IGF-I, 22 6 1; IGFBP-1, 1.6 6 0.1; IGFBP-3, 91 6 3). IGF-I
was more sensitive (100%) than ALS (89%), and both were more
predictive of disease status than IGFBP-3, in that 27% of the patients
had IGFBP-3 levels within the normal range. Considering the ALS/
IGFBP-3 molar ratio, almost 55% of ALS circulated in a free form in
active acromegaly. Before treatment, the IGF-I/IGFBPs (21 1 22 1
23) molar ratio, which can be regarded as free, biologically active,
IGF-I, was greatly increased (0.77 6 0.06; P , 0.0001) compared with
that in control subjects (0.23 6 0.01).
After surgery, all 10 patients with controlled disease showed nor-
malization of ALS (100% sensitivity), whereas 9 of them had normal
IGFBP-3; reevaluation after varying lengths of time showed all these
parameters within the normal range. In the 27 patients with active
disease, IGF-I and ALS were more predictive of disease status (91%
and 83% negative predictive values, respectively) than IGFBP-3
(53%).
The basal ALS concentration correlated only with IGFBP-3 (r 5
0.70; P , 0.001). In postsurgery samples (first control) a statistically
significant (P , 0.001) correlation was found between mean GH val-
ues as well as minimum GH after oral glucose tolerance test and ALS
(r 5 0.72 and 0.83, respectively), IGF-I (r 5 0.69 and 0.77), IGFBP-3
(r 5 0.50 and 0.72), and IGFBP-2 (r 5 20.36 and 20.63). Similarly,
IGF-I, IGFBP-3, and ALS were positively correlated among them-
selves and negatively correlated with IGFBP-2 (P , 0.001).
In conclusion, in the diagnosis of acromegaly, the measurement of
total IGF-I appears to be the most sensitive parameter among the
subunits of the 150K complex, and IGFBP-3 the least sensitive. For
ALS, this subunit is quite sensitive and appears to be a useful pa-
rameter in reassessment after surgical treatment. (J Clin Endocrinol
Metab 86: 1091–1098, 2001)
ACROMEGALY IS characterized by chronic hypersecre-tion of GH. As GH secretion appears pulsatile in ac-
romegalic patients, markers that reflect integrated GH se-
cretion have been sought. The measurement of insulin-like
growth factor I (IGF-I) is widely used in acromegaly for both
diagnosis and follow-up (1, 2), as its circulating levels are
quite stable, its synthesis shows GH dependency, and it
mediates many of the effects of GH. In circulation, most IGF-I
is bound to a GH-dependent complex of 150 kDa (150K
complex) constituted by the IGF-I peptide, a specific IGF-
binding protein (IGFBP-3), and an acid-labile subunit (ALS),
which does not by itself bind IGF-I, but is necessary to
reconstitute the whole complex from purified components
(3–6). The ALS has been shown to be a glycosylated protein
of 84–86 kDa and appears to have the role of increasing the
molecular weight of the IGF-IGFBP-3 complex, which results
in a prolongation of the IGF half-life to about 15 h (4, 5). This
latter aspect is of great importance, as the IGF peptide does
not readily cross the capillary-endothelial barrier in its 150-
kDa form, and the ALS is therefore essential for ensuring
constant plasma IGF levels (7). However, IGF-I measurement
presents methodological problems, mostly due to its asso-
ciation with the IGFBPs in circulation. Current methods of
minimizing IGFBP interference in routine assays are com-
plex, troublesome, and often inefficient (8–10). The IGFBP-3
assay is simpler. However, IGFBP-3 concentrations are vari-
able in acromegalic disease and do not seem always to reflect
the activity of the disease (11, 12).
Despite the recognized GH dependence of the ALS and the
stability of its circulating concentration, few data are cur-
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rently available with regard to its reliability as a parameter
of GH secretory status, and these are often conflicting (13–
15). Experimental and clinical data demonstrate that the ALS,
like IGF-I, is primarily under the control of GH (16–18).
Except in critically ill patients (19–21), the ALS is relatively
independent of mechanisms known to influence IGF-I and
IGFBP-3 secretion (22), thus suggesting that it might be a
more specific parameter of GH secretory status. Moreover, as
its measurement is unaffected by IGFBPs, which may inter-
fere in many conventional IGF-I assays (23), it could offer
several advantages over IGF-I in monitoring the activity of
acromegalic disease. However, ALS measurement is rela-
tively recent, and data on ALS concentrations in acromegaly
are very scarce (23–25).
The aim of the present study is to compare ALS levels in
a group of healthy subjects with those of a group of patients
with active acromegaly. The effects of both successful and
unsuccessful pituitary surgery on ALS levels, as judged by
GH suppression during an oral glucose tolerance test
(OGTT), are also reported. The reliability of the ALS in ac-
romegaly will be considered in comparison with other com-
ponents of the GH-IGF-I axis: GH, IGF-I, IGFBP-1, IGFBP-2,
and IGFBP-3.
Materials and Methods
Patient population and protocol
Forty-five acromegalic patients (23 women and 22 men; age, 21–64 yr)
who had undergone adenomectomy were included in this study. Ac-
romegaly was diagnosed on the basis of clinical features, high serum
IGF-I concentrations compared with the age-adjusted normal range, and
elevated GH levels that were not suppressible to less than 1 mg/L during
an OGTT (26). The duration of the acromegalic disease ranged from 1–20
yr (median, 6 yr). All patients were off medical therapy for acromegaly,
two were receiving replacement therapy with T4, and none was taking
glucocorticoids. Most patients had been newly diagnosed. Four patients
who had received octreotide therapy (300 mg/day, sc) were assessed at
least 1 month after therapy discontinuation. GH concentrations (mean
of at least four fasting samples) were 23.6 6 3.2 mg/L (6sem), ranging
from 2.6–78. 5 mg/L. In 37 patients PRL levels were within the normal
range (,20 mg/L in women and ,15 mg/L in men), whereas 8 patients
had elevated PRL levels ranging from 23–108 mg/L. Gonadal function
was normal in 15 men and 16 women. Six women were in the menopause
and were not receiving hormone replacement therapy; 1 was amenor-
rheic. Seven men had reduced testosterone levels ranging from 2.4–9.1
nmol/L (normal range, 13–42). Two patients had diabetes mellitus: 1
was treated with insulin, and 1 with oral antidiabetic agents. In all
patients the presence of a GH-secreting tumor was confirmed by im-
munohistochemical studies of surgically removed tissue.
Thirty-seven patients were reevaluated 1–6 months after surgery
(first control). None of them had undergone medical therapy. Ten pa-
tients were considered controlled on the basis of GH suppression to less
than 1 mg/L after OGTT and normal IGF-I concentrations compared
with the age-adjusted normal range. In these 10 patients, the abnormal
GH responses present before surgery (to TRH in 7, to sulpiride injected
during dopamine infusion in 2, and to GnRH in 1) had also disappeared.
One patient presenting with IGF-I level above the 97th percentile of the
control group and nadir GH after OGTT below 1 mg/L was considered
to have persistent disease. Two other patients, in whom GH decreased
to 1 mg/L and not less than 1 after OGTT while abnormal GH responses
were maintained, were not considered cured (27). Gonadal function
normalized in 3 men and worsened in 2; all other anterior pituitary
functions were unchanged. Antidiabetic therapies were unmodified.
In 4 of 10 patients with controlled disease and in 21 of 27 with active
disease, further evaluation (second control) was performed 12–36
months after surgery. The uncontrolled group of patients was assessed
while off medical therapy. Seven of these patients had undergone ra-
diotherapy in the meantime.
One hundred age- and sex-matched healthy blood donors volun-
teered as controls (Table 1).
In all patients and normal controls, venous blood samples were taken
in the morning (after overnight fasting) for the determination of IGF-I,
ALS, IGFBP-1, IGFBP-2, and IGFBP-3. Serum was kept at 220 C until
assayed. All pre- and postoperative samples from the same subject were
assessed in the same assay.
Analytical methods
Serum GH levels were determined by an immunofluorimetric assay
(AutoDelfia hGH, Wallac, Inc., Turku, Finland). The sensitivity of the
assay was 0.01 mg/L; the intra- and interassay coefficients of variation
were 2.6% and 3.9%, respectively.
IGF-I was measured by RIA using immunochemicals and tracer pro-
vided by Medgenix (Fleurus, Belgium). The sensitivity of the assay was
1.2 nmol/L; the intra- and interassay coefficients of variation were 6%
and 7.5%, respectively. To avoid interference from binding proteins,
single plasma ethylenediamine tetraacetate samples were treated with
acid-ethanol according to the method of Daughaday et al. (28).
Serum total ALS was measured by means of specific two-site sand-
wich enzyme-linked immunosorbent assay, using anti-ALS antibodies
raised against synthetic amino-terminal and carboxyl-terminal ALS pep-
tides, and reagents and tracer provided by Diagnostics Systems Labo-
ratories, Inc. (Webster, TX). All samples were pretreated to dissociate the
complexed ALS and enhance ALS immunoreactivity. The sensitivity of
the assay was 4.7 nmol/L; the intra- and interassay coefficients of vari-
ation were 5.5% and 7.2%, respectively. Recovery of human serum-
derived glycosylated ALS [purified as described previously (6)] was 75%
for the lower concentration added (1 mg) and 95% for the higher con-
centration added (60 mg).
IGFBP-1 was measured by immunoradiometric assay, using reagents
and tracer provided by Diagnostics Systems Laboratories, Inc. The sen-
sitivity of the assay was 0.05 nmol/L; the intra- and interassay coeffi-
cients of variation were 2.5% and 4.6%, respectively.
IGFBP-2 levels were determined by double antibody RIA using a
nonequilibrium technique, as described by Clemmons et al. (29). Specific
IGFBP-2 antiserum was purchased from Upstate Biotechnology, Inc.
(Lake Placid, NY), and the standard was a pure IGFBP-2 preparation
obtained by DNA recombinant technology (ImmunoKontact, Frankfurt,
Germany). The sensitivity of the assay was 0.01 nmol/L; the intra- and
interassay coefficients of variation were 6% and 9.5%, respectively.
IGFBP-3 was measured by immunoassay, using reagents and tracer
TABLE 1. Comparison between hormone levels in healthy subjects and in untreated acromegalic patients
Parameters Healthy subjects Acromegalic patients P
No. of cases 100 45
Sex (F/M) 0/50 23/22
Age (yr) 43 6 12 (40–45) 39 6 11 (36–42) NS
ALS (nmol/L) 281 6 43 (273–290) 523 6 171 (473–573) ,0.0001
IGF-I (nmol/L) 22 6 4 (21–23) 129 6 39 (118–140) ,0.0001
IGFBP-1 (nmol/L) 1.6 6 1.2 (1.4–1.9) 0.71 6 0.6 (0.5–0.9) ,0.0001
IGFBP-2 (nmol/L) 8.6 6 5.4 (7.6–9.7) 7.5 6 5.8 (5.7–9.1) NS
IGFBP-3 (nmol/L) 91 6 29 (86–97) 234 6 141 (193–275) ,0.0001
Data are shown as the mean 6 SD; 95% confidence intervals are given in parentheses.
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provided by Diagnostics Systems Laboratories, Inc. All samples were
diluted appropriately so as to reach a point in the curve where there is
parallelism among unglycosylated Escherichia coli-derived IGFBP-3, gly-
cosylated Chinese hamster ovary-derived IGFBP-3, and serum (%B/B0,
70–85%). The sensitivity of the assay was 0.04 nmol/L; the intra- and
interassay coefficients of variation were 3.25% and 5.6%, respectively.
Statistical analysis
Statistical analysis was performed by nonparametric test on paired
(Wilcoxon signed rank test) and unpaired (Mann-Whitney test) obser-
vations. P , 0.05 was considered significant. Results are expressed as the
mean 6 sem. The correlations among all parameters studied were eval-
uated using Spearman rank order statistics and linear regression anal-
ysis models. For this purpose, log-transformed values of GH and
IGFBP-3, which showed a log normal distribution, were used. The 97th
percentile of the normal distribution calculated for each age group in the
healthy subjects was chosen as the cut-off point for normal serum levels
of all parameters of the IGF system. Because normal levels are largely
arbitrary and vary according to laboratory, we investigated the diag-
nostic accuracy of each parameter at different cut-off points by
determination of the receiver-operating characteristic (ROC). All statis-
tical analyses were made using SPSS statistical software (SPSS, Inc.,
Chicago, IL).
Results
Healthy subjects
The mean concentrations of the different parameters are
shown in Table 1 and Fig. 1. Analytical distribution of age
and single values of IGF-I, IGFBP-3, and ALS are shown in
Fig. 2.
As expected, a negative correlation between IGF-I and age
and between IGFBP-3 and age (r 5 20.61 for IGF-I and r 5
20.40 for IGFBP-3; P , 0.001 for both) was observed. No
statistically significant correlation was found between ALS
levels and age in the 20–65 yr age range. Indeed, a statisti-
cally significant difference (P , 0.001) between 20- to 35-yr-
old subjects and 50- to 65-yr-old subjects was present for
IGF-I, IGFBP-2, and IGFBP-3, but not for ALS. IGFBP-2 levels
significantly increased with age in women, but not in men
(r 5 0.51; P , 0.01). No other gender differences were found.
ALS concentrations were significantly correlated with IGF-I
(P , 0.0001) and IGFBP-3 levels (P , 0.001). The ALS/
IGFBP-3 molar ratio was 3.4 6 0.1. Overall, the 3rd and 97th
percentiles were 13.3 and 30.1 nmol/L for IGF-I, 216 and 350
nmol/L for ALS, 50 and 136 nmol/L for IGFBP-3, 0.2 and 3.9
nmol/L for IGFBP-1, and 2.4 and 18.7 nmol/L for IGFBP-2.
Acromegalic patients: before surgery
In the group of acromegalic patients ALS levels were el-
evated before transsphenoidal surgery (Table 1 and Figs. 1
and 2). ALS levels were higher than the 97th percentile of
healthy subjects in 40 patients (89%). One of the 5 patients in
FIG. 1. Serum levels of IGF-I, ALS,
IGFBP-3, IGFBP-1, and IGFBP-2 in
100 normal subjects, 45 acromegalic
patients before surgery, and 37 acro-
megalic patients after surgery (11 with
controlled and 26 with active disease).
Data are shown as the mean 6 SEM. F,
P , 0.05; FF, P , 0.001; FFF or ***,
P , 0.0001.
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whom ALS levels were below the 97th percentile of healthy
controls also showed the lowest concentration of GH (mean
value, 2.6 mg/L) and response after OGTT (1.4 mg/L). IGF-I
concentration, although always above the normal range for
age, tended to be lower in these patients than in patients with
high ALS levels. All 5 also showed IGFBP-3 below the 97th
percentile and IGFBP-2 levels in the higher range concen-
tration. The basal ALS concentration correlated with IGFBP-3
(r 5 0.70; P , 0.001). No correlation with age, GH, IGF-I,
IGFBP-1, IGFBP-2, or tumor size was observed in untreated
acromegalic patients. No differences according to gender,
PRL levels, or gonadal status were observed.
IGF-I levels were elevated in all patients compared with
those in normal controls (Table 1 and Figs. 1 and 2), ranging
from 60–197 nmol/L. The IGF-I/IGFBPs (21 1 22 1 23)
molar ratio was significantly (P , 0.001) higher (0.77 6 0.1)
than that in normal subjects (0.23 6 0.01). In contrast with
healthy subjects, the IGF-I concentration did not decrease
with age. A significant correlation was found between IGF-I
and GH mean concentrations and nadir value after OGTT
(r 5 0.44 and 0.59; P , 0.01).
IGFBP-3 levels ranged from 67–717 nmol/L (Table 1 and
Figs. 1 and 2). About two thirds of the patients showed high
IGFBP-3 concentrations, whereas 12 (27%) had IGFBP-3 lev-
els in the normal range. No correlations were found with the
parameters evaluated, apart from ALS.
IGFBP-1 concentrations ranged from 0.08–2.46 nmol/L
and were significantly lower than IGFBP-1 levels in normal
controls (Table 1 and Fig. 1).
IGFBP-2 levels ranged from 1.44–26.37 nmol/L and were
not statistically different from those in controls (Fig. 1). How-
ever, with regard to the IGFBP-2/IGF-I molar ratio, 95% of
patients showed a value below the third percentile of that in
healthy subjects.
None of the parameters considered, apart from GH con-
centration (P , 0.01), correlated with the size of the adenoma.
Information on the discriminatory ability of each param-
eter evaluated by ROC curve analysis (Fig. 3) was in close
agreement with the estimates obtained using the cut-off
points from normal controls (97th percentile).
No ROC curve for IGF-I could be obtained, as discrimi-
nation between acromegalic patients and normal controls was
total, with no overlapping of the values in the two groups. The
areas under the curve for ALS, IGFBP-3, IGFBP-1, and IGFBP-2
were 0.937, 0.892, 0.798, and 0.584, respectively, indicating that
the parameter with the best discrimination, after IGF-I, was
ALS, followed by IGFBP-3.
FIG. 2. Serum IGF-I, IGFBP-3, and ALS in normal subjects and in 45 acromegalic patients before and after surgery. Dashed lines represent
the 3rd, 50th, and 97th percentiles of the control group.
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Acromegalic patients: reevaluation after surgery
Thirty-seven patients were reevaluated after transsphe-
noidal surgery. Mean levels of the different parameters be-
fore and after surgery are shown in Fig. 1. All parameters
showed the expected modifications after removal or reduc-
tion of the adenoma; GH, IGF-I, and IGFBP-3 decreased,
whereas IGFBP-1 and IGFBP-2 increased. The sensitivity,
specificity, and positive and negative predictive values of
ALS, IGF-I, and IGFBP-3 in identifying patients with con-
trolled and active disease are shown in Table 2.
Surgery was considered successful in 10 patients, in whom
an oral glucose tolerance test suppressed GH concentrations
below 1 mg/L, and IGF-I was normalized. Before surgery,
this group of patients had significantly lower levels of ALS
(381 6 52 vs. 510 6 15; P , 0.002) and IGFBP-3 (112 6 14 vs.
230 6 17; P , 0.0001) and significantly higher levels of
IGFBP-2 (12.0 6 2.1 vs. 5.7 6 0.6; P , 0.005) than patients in
whom surgery was unsuccessful. After successful surgery, 10
controlled patients showed normal concentrations of ALS,
thus confirming good control of the disease, whereas one
patient presented with an IGFBP-3 concentration slightly
above the 97th percentile of the control group (Fig. 2 and
Table 2). In 4 controlled patients, reevaluation after varying
lengths of time (control 2) showed IGF-I, IGFBP-3, and ALS
concentrations in the normal range.
Twenty-six of the 27 patients in whom surgery was un-
successful had elevated IGF-I concentrations, whereas 2 (7%)
and 8 (30%) showed normal ALS and IGFBP-3, respectively
(Fig. 2 and Table 2). Reevaluation of the only patient who had
presented with IGF-I, IGFBP-3, and ALS concentrations at
the upper end of the normal range at the first control revealed
increased concentrations of IGF-I and ALS, but not IGFBP-3.
The other patient with ALS below the normal range, but
IGF-I above the 97th percentile of the control group, showed
FIG. 3. ROC assessed the comparative diagnostic performance of ALS, IGFBP-3, IGFBP-1, and IGFBP-2. The ROC curve for IGF-I cannot be
estimated because there was no overlap between values in cases and in controls (sensitivity, 100%; specificity, 100%).
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a nadir GH less than 1 mg/L after an OGTT and normal
IGFBP-3. Reevaluation of this patient showed normalization
of all parameters, including IGF-I concentration. Therefore,
in 20 of 21 patients who were reevaluated (control 2), ele-
vated concentrations of IGF-I and ALS persisted, ranging
from 60–120 and from 382–976 nmol/L, respectively,
whereas IGFBP-3 levels were normal in 5 patients.
IGFBP-1 levels increased slightly, although not signifi-
cantly, in both controlled and uncontrolled patients (Fig. 1).
IGFBP-2 levels and IGFBP-2/IGF-I ratio increased signif-
icantly only in the group of controlled patients (Table 1 and
Fig. 1). All patients with controlled disease showed a sig-
nificantly increased (P , 0.001) IGFBP-2/IGF-I ratio in both
postsurgical follow-up examinations, whereas 23 of 26 pa-
tients with active disease showed a ratio lower than the third
percentile of that of the normal population.
In postsurgery samples (first control) a statistically signif-
icant (P , 0.001) correlation was found between mean GH
values (Fig. 4) as well as minimum GH after OGTT and ALS
(r 5 0.72 and 0.83, respectively), IGF-I (r 5 0.69 and 0.77),
IGFBP-3 (r 5 0.46 and 0.67), and IGFBP-2 (r 5 20.36 and
20.63). Similarly, IGF-I, IGFBP-3, and ALS were positively cor-
related among themselves and negatively correlated with
IGFBP-2 (P , 0.001).
FIG. 4. Correlations between IGF-I, ALS, and IGFBP-3 concentrations and mean GH concentration in acromegalic patients before and after
transsphenoidal surgery.
TABLE 2. Sensitivity, specificity, and predictive values of IGF-I, IGFBP-3, and ALS in 37 acromegalic patients reevaluated 1–6 months
after surgery
All patients
(n 5 37) Patients with controlled disease (n 5 10) Patients with active disease (n 5 27) PPV NPV
IGF-I Specificity, 100% False positive, 0% Sensitivity, 96% False negative, 4%
Normal 11 (30%) n 5 10 n 5 1 91%
Elevated 26 (70%) n 5 0 n 5 26 100%
IGFBP-3 Specificity, 90% False positive, 10% Sensitivity, 70% False negative, 30%
Normal 17 (46%) n 5 9 n 5 8 53%
Elevated 20 (54%) n 5 1 n 5 19 95%
ALS Specificity, 100% False positive, 0% Sensitivity, 93% False negative, 7%
Normal 12 (32%) n 5 10 n 5 2 83%
Elevated 25 (68%) n 5 0 n 5 25 100%
Data are given as the percentage of outcome of treatment. PPV and NPV, Positive and negative predictive values, respectively.
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Discussion
As the subunits of the 150K complex are GH dependent
and stable in circulation, they constitute a sensitive and spe-
cific index of integrated 24-h GH secretion, and their use can
avoid causing the patient the stress of multiple sampling for
evaluation of the GH secretory state. Several studies have
established the high specificity and sensitivity of the total
IGF-I concentration in the diagnosis of acromegaly (1, 2, 30),
whereas data on the reliability of IGFBP-3 are conflicting, and
those on ALS are scant, even though their measurement is
less difficult, as it does not require previous extraction. Un-
fortunately, some well known limitations of IGF-I, resulting
from its age dependency and its modification in some clinical
conditions (malnutrition, diabetes, hypothyroidism, and
chronic renal failure) are more or less shared by the other
subunits of the 150K complex. All of these limitations, how-
ever, can easily be overcome by means of specific testing for
individual diseases and by defining normal ranges with ref-
erence to a large number of age- and sex-matched control
subjects. In this respect it is noteworthy that ALS levels in 20-
to 65-yr-old normal subjects appear to be less age dependent
than IGF-I and IGFBP-3. This finding is in agreement with the
data reported by Juul et al. (31) in adult women, although we
did not find a significant decrease in ALS levels in adult men.
Our data in normal subjects confirm that the molar concen-
tration of ALS in the circulation exceeds that of IGFBP-3 by
about two thirds (23), and that its concentration is positively
correlated with IGF-I and IGFBP-3 concentrations (25).
The present study, carried out by comparing a large num-
ber of acromegalic patients with 100 healthy adults, shows
that active acromegaly is characterized by elevated ALS con-
centrations. Previous data are concordant with our finding
that ALS levels in acromegalic patients are about twice those
present in normal subjects. Indeed, using an antibody raised
against serum-derived glycosylated ALS, Baxter (24) first
showed that ALS levels were elevated in acromegalic pa-
tients and, using the same RIA, Hoffman et al. (15) reported
mean ALS levels 2.5-fold above the normal mean and 91% of
patients with values above the normal range. More recently,
using the same two-site sandwich enzyme-linked immu-
nosorbent assay as we used, Khosravi et al. (25) found mean
ALS levels in 20 acromegalics about 1.6-fold above the mean
of control value, and 80% of patients above the normal range.
In the 45 acromegalic patients evaluated in this study, patho-
logical ALS levels were found in 89% of patients before
treatment. In the remaining 5 patients, we could not find any
known cause shared by all to justify ALS levels within the
normal range. However, we cannot exclude that the complex
regulatory mechanisms modulating the circulating levels of
the 150K complex (16–22) might differently affect the syn-
thesis of each subunit, at least in some patients. Nevertheless,
in this subset of patients GH levels and IGF-I concentrations
tended to be lower, and IGFBP-2 levels higher, than in pa-
tients with pathological ALS levels. The finding that all of
them also showed IGFBP-3 below the normal range confirms
the close association of these two components of the 150K
complex. Indeed, the findings that multiple linear regression
analysis indicates that ALS is the factor most closely associated
with IGFBP-3 concentration (P , 0.005) and that ALS/IGFBP-3
molar ratio found in acromegalic patients does not differ sig-
nificantly from that seen in normal subjects are in agreement
with the hypothesis that much of the apparent GH dependency
of serum IGFBP-3 might be secondary to its stabilization by ALS
(32). Considering the ALS/IGFBP-3 molar ratio, almost 55% of
ALS should circulate in a free form in acromegaly. In agreement
with data reported by Juul et al. (33), not only the IGF-I/IGFBP-3
molar ratio but also the IGF-I/IGFBPs (21 1 22 1 23) ratio,
which can be regarded as free, biologically active, IGF-I, was
greatly increased in patients with active acromegaly. This in-
crease was more closely related to the increased IGF-I synthesis
and the elevated IGF-I/IGFBP-3 molar ratio than to the reduc-
tion of the IGFBPs negatively regulated by GH. Indeed, IG-
FBP-2 was unchanged, and IGFBP-1 was, on the average, only
half that seen in control subjects.
In the acromegalic patients before treatment, the levels of
total IGF-I and IGFBP-3 were increased in 100% and 73% of
patients, respectively. The finding regarding the poor reliability
of IGFBP-3 in the diagnosis of acromegaly is in agreement with
several previous reports showing that from 26–45% of patients
have IGFBP-3 levels overlapping with those of healthy controls
(11, 12, 34, 35), although in one study (36) elevated levels of
IGFBP-3 were found in all 18 untreated acromegalic patients.
In postsurgical reassessment of the disease, it is notewor-
thy that ALS shows a positive predictive value equal to that
of IGF-I (100%) and a negative predictive value slightly lower
(83%) than that of IGF-I (91%), whereas IGFBP-3 again shows
the lowest sensitivity and specificity.
Although GH exerts an inhibitory effect on the synthesis of
IGFBP-1 as well as IGFBP-2 (29, 38), IGFBP-1 is not usually
considered, because, unlike IGFBP-3 and IGFBP-2, it shows
marked diurnal variations due to changes in metabolic status
(38). Moreover, owing to its short half-life and lower circulating
levels, IGFBP-1 does not usually play an important role in
stabilizing circulating IGFs (39). The observation that IGFBP-1
levels were lower in acromegaly than in normal subjects is in
agreement with previous reports (33, 40, 41) and with the
known inhibition of this parameter by insulin (38). After sur-
gery, IGFBP-1 levels increased, reaching statistical significance
only in the group of controlled patients. Jørgensen et al. (41)
found serum IGFBP-1 levels to be slightly supernormal after
adenomectomy; this finding was not confirmed by our data,
according to which IGFBP-1 only normalized.
Although IGFBP-2 levels significantly lower than those in
healthy subjects have been reported in acromegalics (33, 41,
42), our data, in agreement with those reported by Clemmons
et al. (29), showed IGFBP-2 concentrations not significantly
different from those found in a large group of normal sub-
jects. With regard to the IGFBP-2/IGF-I molar ratio, 94% of
patients showed a ratio below the third percentile of healthy
subjects, and this ratio normalized in controlled patients.
After surgery, IGFBP-2 greatly increased in the group of
controlled patients, without any significant change in not
controlled patients, thus suggesting that elevated GH and
IGF-I indeed have an effect on IGFBP-2.
In postoperative samples, GH secretion (mean values as
well as nadir GH after OGTT) correlated mostly with ALS
and IGF-I and to a lesser extent with IGFBP-3. Our previous
finding of a log-linear correlation between GH and IGF-I (2)
is further corroborated by this study and extended to the ALS
subunit and to IGFBP-3.
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In conclusion, our data show that active acromegaly is
characterized by elevated ALS concentrations as well as el-
evated total and free IGF-I levels. Mean levels of IGFBP-3
were also higher, whereas levels of IGFBP-1 were lower than
those in normal subjects. However, one quarter of the pa-
tients had IGFBP-3 levels in the normal range, and most of
these showed normal IGFBP-1 and IGFBP-2 concentrations.
These observations are equally true when considering newly
diagnosed patients and patients with active disease after
pituitary surgery. Therefore, in the diagnosis of acromegaly,
the measurement of total IGF-I appears to be the most sen-
sitive parameter among the subunits of the 150K complex,
and IGFBP-3 the least sensitive. For what concerns ALS, this
subunit is seen to be quite sensitive and appears to be a useful
parameter in reassessment after surgical treatment.
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